2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN

EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN

Back to course

Pdf Summary

This study evaluates the real-world outcomes of patients with extensive disease small cell lung cancer (ED-SCLC), using data from the International Lung Cancer Consortium (ILCCO) dataset. The analysis aims to assess overall survival (OS) rates in ED-SCLC and compare them with control arms of the pivotal CASPIAN and IMpower133 trials, which introduced immunotherapy alongside conventional chemotherapy.<br /><br />Key findings indicate that the introduction of immunotherapy has had a notable impact on clinical practice, but it has not significantly changed real-world outcomes in the last 30 years prior to its implementation. The median OS for the ILCCO dataset and the control arms of CASPIAN and IMpower133 was approximately 10.3 months, suggesting similar survival outcomes.<br /><br />The cohort was assessed internationally with data from 19 sites across Asia, North America, and Europe, thereby supporting the global applicability of the CASPIAN and IMpower133 trial results. The demographic characteristics from the ILCCO dataset reveal that patients were mostly male, white, and ever-smokers, aligning with profiles reported in the trial control arms. <br /><br />OS probabilities were calculated using the Kaplan-Meier estimator, and factors influencing survival were characterized employing Cox regression analysis. The study found that age and sex were statistically significant prognostic factors in a multivariable analysis. Over the years, improvements in survival probabilities were noted with advances in treatment spread, showing a slight increase in survival over decades, though median OS remained consistent at 10.3 months.<br /><br />This multinational study highlights the consistency of real-world data with controlled trial outcomes and underscores the importance of ongoing improvements and assessments in ED-SCLC treatment strategies.

Asset Subtitle

Sam Khan

Meta Tag

Speaker Sam Khan

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive disease small cell lung cancer

ED-SCLC

International Lung Cancer Consortium

ILCCO dataset

overall survival

CASPIAN trial

IMpower133 trial

immunotherapy

Kaplan-Meier estimator

Cox regression analysis